Treatment of Disseminated High Grade Lymphoma

NCT00536393 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Doxorubicin
DRUG: Doxorubicin pegylated

Sponsor

French Innovative Leukemia Organisation